Abstract: The present invention provides a means of selectively killing epithelial cell carcinomas by administering a CXCR4-specific sequence of the Gp120 protein or Nef proteins or the proteins themselves (the modulators) such as that found in strains HIV-1, HIV-2, SIV, or FIV CXCR4-specific Gp 120 sequences or Nef proteins or sequences may be delivered to the mucosa or systemically. The mucosal means of application include oral, intranasal, ocular, intravaginal, rectal, and/or intraurethral administration in liquid or particulate form.

Abstract: This invention provides means of enhancing immune response, particularly mucosal immune response, by administration of an immune-enhancing effective amount of an epithelial growth factor, CC or C×C a chemokine in a pharmaceutically acceptable carrier. Epithelial growth factor and CC or C×C chemokines may be delivered to the mucosa in conjunction with antigen to provide improved cell-mediated immune response to the antigen. Mucosal means of application include oral, intranasal, ocular, intravaginal, rectal and/or intraurethral administration in liquid or particulate form. The adjuvants may, additionally, be added to liquids or solids for administration. For example, the adjuvants of the invention may be administered in feed or water or on solid supports such as sponges and fabrics. The vaccines with the adjuvants may be administered in or on baits.